Not exact matches
«I hope that someday all of you on the advisory committee can tell your families for generations that you were part of the process that ended the use of toxic treatments like
chemotherapy and radiation as standard treatment, and turned blood cancers into a treatable disease that even
after relapse most people survive.»
Approximately one year
after successful treatment with cytotoxic
chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally
relapse with recurrence of tumours that are resistant to further
chemotherapy.
A majority of patients (80 %) experience a
relapse after their initial treatment with
chemotherapy, therefore a more effective line of treatment is needed.
Dr. Rassool says that a clinical trial is planned to test whether low doses of a DNMT inhibitor, decitabine, and an investigational PARP inhibitor, talazoparib, can be safely combined and whether this therapy shows efficacy for AML patients, especially those who can not receive intensive
chemotherapy, whose leukemia is resistant to treatment, or who have experienced a
relapse after treatment.
Many cancer patients that receive
chemotherapy go into remission at first, but
relapse after treatment is discontinued.
More than 80 percent of women with advanced stage high - grade serous ovarian cancer experience
relapses even
after repeated surgeries and multiple rounds of
chemotherapy, and this effective new approach to treat the disease could be a major step forward in preventing cancer from returning.
Treating patients with high - dose radiotherapy
after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local
relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.
A Phase 3 Open - Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage
Chemotherapy in Subjects with FLT3 - ITD Positive Acute Myeloid Leukemia (AML) Refractory To or
Relapsed After First - line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Platinum - sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery
after relapse on platinum
chemotherapy experience longer progression - free survival.
FLT3 mutations are more common in patients with normal karyotype and appear to be associated with a higher rate of
relapse after conventional
chemotherapy.
Some forms respond better to
chemotherapy though most dogs will
relapse after a period of remission.
If your dog has a
relapse after treatment, in most cases another treatment series of
chemotherapy has shown to be effective.
Fifteen of 19 (79 %) vaccinated dogs in Group 2 eventually
relapsed, but 4 dogs (21 %) did not and achieved a durable (> 16 months) first remission
after chemotherapy and CD40 - B vaccination.
Owners must be willing to return to UW Veterinary Care one week
after initiation of
chemotherapy, as well as at the time of
relapse.
In January of this year, six weeks
after completing a year of
chemotherapy, radiation and multiple surgeries, she suffered a
relapse.